Shree Ganesh Remedies Falls to 52-Week Low of Rs.442.1 Amidst Continued Downtrend

Stock Price Movement and Market Context

On 25 Nov 2025, Shree Ganesh Remedies recorded an intraday low of Rs.442.1, representing a 4.05% drop during the trading session. The stock has declined for two consecutive days, accumulating a total return of -3.75% over this period. This performance contrasts with the broader market, where the Sensex opened higher at 85,008.93 points, gaining 108.22 points (0.13%) before trading slightly lower at 84,989.38 points, still maintaining a position close to its 52-week high of 85,801.70 points.

While the Sensex and BSE Small Cap indices showed modest gains, Shree Ganesh Remedies underperformed its sector by 1.76% today. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish trend in the short to long term.

Financial Performance and Profitability Trends

Over the past year, Shree Ganesh Remedies has experienced a notable decline in its financial metrics. The company’s profit before tax (PBT) for the most recent quarter stood at Rs.6.02 crores, reflecting a fall of 28.76% compared to previous periods. Similarly, the profit after tax (PAT) for the quarter was Rs.4.96 crores, down by 22.6%. These figures contribute to the overall negative returns of -34.59% for the stock over the last 12 months, a stark contrast to the Sensex’s positive return of 6.09% during the same timeframe.

The company’s return on capital employed (ROCE) for the half-year period is recorded at 16.18%, which is among the lower levels observed recently. Return on equity (ROE) stands at 13.3%, indicating moderate profitability relative to shareholder equity. Despite these challenges, the company maintains a low debt-to-EBITDA ratio of 0.47 times, suggesting a manageable debt burden and capacity to service its financial obligations.

Valuation and Market Position

Shree Ganesh Remedies is currently trading at a price-to-book value of 3.8, which is considered fair relative to its historical valuations and peer group. However, the stock price at Rs.442.1 is significantly below its 52-week high of Rs.950, indicating a substantial correction in market valuation over the past year.

Despite the company’s size and presence in the Pharmaceuticals & Biotechnology sector, domestic mutual funds hold no stake in Shree Ganesh Remedies. This absence of institutional ownership may reflect a cautious stance towards the stock’s current valuation and recent financial performance.

Comparative Market Performance

In the last year, Shree Ganesh Remedies has underperformed not only the Sensex but also the broader BSE500 index, which generated returns of 4.66%. The stock’s negative return of -34.59% highlights the divergence from market trends and sectoral performance. While the pharmaceutical sector has seen mixed results, the company’s share price trajectory has remained subdued.

Sector and Industry Context

Operating within the Pharmaceuticals & Biotechnology sector, Shree Ganesh Remedies faces a competitive environment where innovation, regulatory approvals, and market penetration are critical factors. The sector has witnessed varied performances, with some companies benefiting from increased demand and others facing pricing pressures and regulatory scrutiny.

Shree Ganesh Remedies’ current market cap grade is 4, reflecting its mid-sized presence within the industry. The stock’s recent price movements and financial results suggest that it is navigating a challenging phase compared to its peers.

Summary of Key Metrics

To summarise, the stock’s key financial and market indicators as of 25 Nov 2025 are:

• 52-week low price: Rs.442.1


• 52-week high price: Rs.950


• One-year stock return: -34.59%


• Sensex one-year return: 6.09%


• Quarterly PBT: Rs.6.02 crores (-28.76%)


• Quarterly PAT: Rs.4.96 crores (-22.6%)


• ROCE (Half Year): 16.18%


• ROE: 13.3%


• Debt to EBITDA ratio: 0.47 times


• Price to Book Value: 3.8

These figures provide a comprehensive view of the company’s current financial standing and market valuation.

Conclusion

Shree Ganesh Remedies’ fall to a 52-week low of Rs.442.1 reflects a period of subdued performance and valuation pressures. The stock’s decline contrasts with broader market gains and sectoral trends, underscoring the challenges faced by the company in recent quarters. While the company maintains a manageable debt profile and moderate profitability ratios, its recent financial results and market performance have contributed to the current valuation levels.

Investors and market participants will continue to monitor the stock’s price movements and financial disclosures as the company navigates this phase within the Pharmaceuticals & Biotechnology sector.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →